Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Concurrent oral delivery of non-oncology drugs through solid self-emulsifying system for repurposing in hepatocellular carcinoma
CONCLUSION: The current study revealed a non-oncology drug combination effective against hepatocellular carcinoma. Further, it is concluded that the developed S-SEDDS containing non-oncology drug combination alone and in combination with DTX could be a promising alternative to toxic chemotherapeutics for the effective oral treatment of hepatic cancer.PMID:37216496 | DOI:10.1080/03639045.2023.2216785 (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - May 22, 2023 Category: Drugs & Pharmacology Authors: Rameshwar M Ardad Arehalli S Manjappa Shashikant C Dhawale Popat S Kumbhar Yogesh V Pore Source Type: research
